DOUGLAS LEVINE was named director of the Division of Gynecologic Oncology at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, effective May 15. Levine joins NYU Langone from Memorial Sloan Kettering Cancer Center, where he served as an attending physician and head of the Gynecology Research Laboratory. He also served as... […]
The Clinical Cancer Letter received a rebuttal letter for publication from the GOG Foundation and its president, Philip DiSaia, regarding the article “Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response Than Paclitaxel Therapy Alone” which appeared in the March 2016 issue.
FDA granted accelerated approval to Venclexta tablets (venetoclax) for patients diagnosed with chronic lymphocytic leukemia with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy.
NCI CTEP-Approved Trials for the Month of April
Researchers at UC Davis have shown that radiation therapy following surgery benefits older patients more than younger patients when treating soft tissue sarcomas.
A five-year study showed that stereotactic body radiation therapy to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.
Overall survival data from CheckMate-069, a phase II trial of a Opdivo and Yervoy combination regimen in patients with previously untreated advanced melanoma, demonstrated a two-year overall survival rate of 69 percent compared to 53 percent for Yervoy alone (HR=0.58 [95% CI: 0.31-1.08]) in patients with BRAF wild-type advanced melanoma.
A phase III trial of farletuzumab failed to meet its endpoints of significantly increasing progression-free survival or overall survival in ovarian cancer patients.
A phase III trial of PD-1 inhibitor Opdivo showed significant survival benefit at one year—compared to investigator's choice of methotrexate, docetaxel or cetuximab—in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
FDA approved Gilotrif (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy.
